Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents

NCT03343444 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C Virus Infection, Response to Therapy of

Interventions

DRUG: 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
DRUG: 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)

Sponsor

Egyptian Liver Hospital